Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

10 567.0 565.0

Investing activities

Movement in restricted cash (9.7) 0.7

Purchase of subsidiary undertaking, net of

cash and cash equivalents acquired (2,458.6) (0.8)

Expenses relating to the New River acquisition (61.0) -

Loan repaid by ID Biomedical Corporation (IDB) - 70.6

Purchase of property, plant and equipment (PP&E) (93.7) (68.7)

Purchase of intangible assets (223.0) (173.6)

Purchase of available-for-sale financial

assets (63.2) (9.8)

Net decrease in current financial assets 55.8 6.9

Proceeds/deposits received from sale of

product rights 234.4 63.4

Proceeds from sale of PP&E 0.8 3.4

Proceeds from sale of available-for-sale

financial assets 0.5 -

Interest received 52.5 47.2

Dividend received from associates 2.3 0.4

Dividend from joint venture 6.8 5.8

__________ __________

Net cash used in investing activities (2,556.1) (54.5)

__________ __________

Financing activities

Proceeds from issue of Shire 2.75% convertible

bonds due 2014 8 1,100.0 -

Redemption of New River 3.75% convertible

notes due 2013 (279.4) -

Redemption of 2% guaranteed convertible loan

notes 2011 -
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... 01, 2015 , ... Research conducted by Synedgen Inc.’s Director ... School of Medicine, Frederick National Laboratory for Cancer Research, and the Centers for ... Access journal. , Christopher Ryan PhD, of Synedgen, and Aparajita Chatterjee, Daniel ...
(Date:9/1/2015)... DUBLIN , September 1, 2015 ... appointment of Sara Mathew to its Board of ... member of the Audit, Compliance & Risk Committee of the ... 1, 2015. Sara previously served as Chairman, President ... retiring in December 2013. During her 12-year tenure at D&B, ...
(Date:8/31/2015)... GUELPH, ON , Aug. 31, 2015 /PRNewswire/ - BIOREM ... new orders totalling $5.7 million. The orders are for air emission ... "Of particular note is a large order for a ... our equipment will be replacing a competitor,s system that failed ... see in our engineered solutions," said Derek S. Webb ...
(Date:8/31/2015)... MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) aclinical ... lead antibody, HuMab 5B1, will be garnering major attention ... upcoming World Molecular Imaging Congress (WMIC) being held in ... from the Department of Radiology at Memorial Sloan Kettering ... of MabVax,s lead antibody as a PET imaging agent ...
Breaking Biology Technology:Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Shire Appoints Sara Mathew to Board of Directors 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4
... (Nasdaq: OREX ), a biopharmaceutical company focused on ... third quarter ended September 30,2010 on Wednesday, November 3, 2010 ... a live webcast and conference call at 5:00 p.m. Eastern ... and webcast to discuss financial results and recent business highlights. ...
... (Nasdaq: UTHR ) today announced its results of operations ... for the third quarter of 2010 were $171.0 million, up from ... the third quarter of 2010 was $39.7 million, or $0.70 per ... per basic share, for the same quarter in 2009. Gross margin ...
... the Human Genome -- REYKJAVIK, Iceland, October 27, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Biology Technology:United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 2United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 3United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 4United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 5United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 6United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 7The New deCODE Map of the Human Genome 2The New deCODE Map of the Human Genome 3The New deCODE Map of the Human Genome 4The New deCODE Map of the Human Genome 5The New deCODE Map of the Human Genome 6The New deCODE Map of the Human Genome 7The New deCODE Map of the Human Genome 8The New deCODE Map of the Human Genome 9
(Date:8/12/2015)... August 12, 2015 As the ... payment innovation and advanced biometrics technology is accelerating beyond ... consumers rely on using their credit cards, the digital ... future for payment services led by companies in the ... :  Google, Inc. (NASDAQ: GOOG ), Apple Inc. ...
(Date:8/11/2015)... 2015 Today, ZUK announced its Android smartphone ... as expected revenues in 2015 that relate to sales of FPC1155 ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO ... prominent smartphone manufacturer in China ... FPC1 155 for Z1 , ...
(Date:8/6/2015)... 6, 2015  Today, U.S. Congressman Mike ... ™ to learn firsthand how Silicon Valley technologies ... is a world leader in multi-factor identity management ... helping federal agencies and commercial organizations achieve new ... "The vast majority of network breaches can ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2
... Active management of the third stage of labour means ... approach, reveals a thesis from the University of Gothenburg, Sweden, ... studies in the West have shown that heavy bleeding following ... thesis, midwife and researcher Elisabeth Jangsten decided to look at ...
... ANN ARBOR, Mich---University of Michigan researchers have determined ... tumors, providing new evidence that the deadliest form of ... cancer stem cell model. In addition, the researchers ... by switching various genes on and off, making the ...
... the massive glaciers of the greater Himalayan region are ... help the region,s communities prepare for the many ways ... to a new report. Programs that integrate health, education, ... address these impacts, the report states. "The extremely high ...
Cached Biology News:Active management of the third stage of labor reduces risk of bleeding 2More evidence that melanoma does not conform to the cancer stem cell model 2More evidence that melanoma does not conform to the cancer stem cell model 3Time to prepare for climate change 2Time to prepare for climate change 3Time to prepare for climate change 4Time to prepare for climate change 5
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... was developed for culturing hybrid cells that ... consists of doubling the amino acids and ... concentrations have been altered as well. This ... liter, which may render it unsuitable for ...
... is an 18 amino acid synthetic peptide whose sequence corresponds to ... peptide is (amino to carboxy terminus): M(1) - A - S ... A - S - P - R - D - A ... peptide may be used for neutralization and control experiments with the ...
... EpiTect Bisulfite Kit enables complete conversion ... less than 6 hours. The highly ... against DNA degradation and a spin-column-based ... fast and reliable results for all ...
Biology Products: